Evaluation of pharmacokinetic, pharmacodynamic, efficacy, and safety data of low-dose ticagrelor versus standard dose in East Asians: a systematic review

References

• BonacaMPBhattDLCohenMLong-term use of ticagrelor in patients with prior myocardial infarctionN Engl J Med2015372191791180025773268
   PubMed Web of Science ®Google Scholar
• ButlerKTengRPharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteersBr J Clin Pharmacol2010701657720642549
   PubMed Web of Science ®Google Scholar
• ZhouDAnderssonTBGrimmSWIn vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kineticsDrug Metab Dispos201139470371021177984
   PubMed Web of Science ®Google Scholar
• HustedSEmanuelssonHHeptinstallSPharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirinEur Heart J20062791038104716476694
   PubMed Web of Science ®Google Scholar
• van GiezenJJNilssonLBerntssonPTicagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregationJ Thromb Haemost2009791556156519552634
   PubMed Web of Science ®Google Scholar
• WallentinLBeckerRCBudajATicagrelor versus clopidogrel in patients with acute coronary syndromesN Engl J Med2009361111045105719717846
   PubMed Web of Science ®Google Scholar
• Brilinta® (ticagrelor) [package insert]Wilmington, DEAstraZeneca L2011
   Google Scholar
• GotoSHuangCHParkSJTicagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome – randomized, double-blind, phase III PHILO studyCirc J201579112452246026376600
   PubMed Web of Science ®Google Scholar
• SerebruanyVTomekAPyaYInferiority of ticagrelor in the PHILO trial: play of chance in East Asians or nightmare confirmation of PLATO-USA?Int J Cardiol201621537237627128564
   PubMed Web of Science ®Google Scholar
• AsanoTKobayashiYFukushimaKSafety and efficacy of low-dose clopidogrel in Japanese patients undergoing coronary stenting, preliminary 30-day clinical outcomeCirc J200872101707170818762704
   PubMed Web of Science ®Google Scholar
• FukushimaKKobayashiYKitaharaHAntiplatelet effect of 50-mg maintenance dose of clopidogrel compared to 200 mg ticlopidine: a preliminary studyHeart Vessels2010251414420091397
   PubMed Web of Science ®Google Scholar
• OhkuboKKobayashiYLong-term safety and efficacy of low-dose clopidogrel in Japanese patients undergoing coronary stenting: a preliminary studyCardiovasc Interv Ther201126210410824122530
   PubMedGoogle Scholar
• YokoiHKimuraTIsshikiTPharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary interventionThromb Res2012129562362822178576
   PubMed Web of Science ®Google Scholar
• KimuraTIsshikiTOgawaHRandomized, double-blind, dose-finding, phase II study of prasugrel in Japanese patients undergoing elective percutaneous coronary interventionJ Atheroscler Thromb201522655756925737192
   PubMed Web of Science ®Google Scholar
• SaitoSIsshikiTKimuraTEfficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS studyCirc J20147871684169224759796
   PubMed Web of Science ®Google Scholar
• [Clopidogrel tablet 25 mg “AA”/Clopidogrel tablet 75 mg “AA”] [PMDA web site] Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/470007_3399008F1033_2_01Accessed July 8, 2016 Japanese
   Google Scholar
• [Effient tablet 2.5 mg/Effient tablet 37 5 mg/Effient tablet 5 mg/Effient tablet 20 mg] [PMDA web site] Available from: http://www.info.pmda.go.jp/go/pack/3399009F1020_1_11/Accessed July 8, 2016 Japanese
   Google Scholar
• TengRButlerKPharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteersInt J Clin Pharmacol Ther201452647849124755129
   PubMed Web of Science ®Google Scholar
• LiHButlerKYangLPharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre studyClin Drug Investig20123228797
   PubMed Web of Science ®Google Scholar
• LiPGuYYangYLow-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trialSci Rep20162431838
   Web of Science ®Google Scholar
• LiKXuYHanQ[Safety and efficacy of low-dose ticagrelor in patients with unstable angina pectoris and non-revascularization]Chin J New Drugs2015242124802484 Chinese
   Google Scholar
• XueHJShiJLiuBComparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACSPlatelets201627544044526830862
   PubMed Web of Science ®Google Scholar
• HiasaYTengREmanuelssonHPharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery diseaseCardiovasc Interv Ther201429432433324935072
   PubMedGoogle Scholar
• LiHGuoJCarlsonGFPharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery diseaseBr J Clin Pharmacol201682235236127038001
   PubMed Web of Science ®Google Scholar
• BonacaMPBhattDLStoreyRFTicagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery diseaseJ Am Coll Cardiol201667232719272827046162
   PubMed Web of Science ®Google Scholar
• AhmadTVooraDBeckerRThe pharmacogenetics of antiplatelet agents: towards personalized therapy?Nat Rev Cardiol201181056057121826075
   PubMed Web of Science ®Google Scholar
• WangHWangXEfficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndromeTher Clin Risk Manag2016121101110527471389
   PubMed Web of Science ®Google Scholar
• StoreyRFAngiolilloDJBonacaMPPlatelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 TrialJ Am Coll Cardiol201667101145115426965534
   PubMed Web of Science ®Google Scholar
• JeongYH“East asian paradox”: challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndromeCurr Cardiol Rep201416548524668607
   PubMed Web of Science ®Google Scholar
• LevineGNJeongYHGotoSExpert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCINat Rev Cardiol2014111059760625154978
   PubMed Web of Science ®Google Scholar
• LutseyPLCushmanMSteffenLMPlasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA studyJ Thromb Haemost20064122629263517002663
   PubMed Web of Science ®Google Scholar
• Kelley-HedgepethALloyd-JonesDMColvinAEthnic differences in C-reactive protein concentrationsClin Chem20085461027103718403563
   PubMed Web of Science ®Google Scholar
• ShenAYYaoJFBrarSSRacial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillationJ Am Coll Cardiol200750430931517659197
   PubMed Web of Science ®Google Scholar